fungal infections

Basilea Pharmaceutica Ltd secures non-dilutive refinancing from funds managed by Athyrium Capital Management, LP for its outstanding 2022 convertible bonds

Ad hoc announcement pursuant to Art. 53 LR (PRESS RELEASE) BASEL/ ALLSCHWIL, 7-Sep-2022 — /EuropaWire/ — Basilea Pharmaceutica Ltd (SWX:…

2 years ago

U.S. FDA designated Basilea Pharmaceutica’s isavuconazole as Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis

Basel, Switzerland, 11-12-2013 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated…

10 years ago

Basilea announced improved operating results in its H1-2013 financials

Continued improvement in financial performance Cash and short-term investments of CHF 262.8 million Guidance on isavuconazole phase 3 topline data…

11 years ago